SynthesisBMC pulmonary medicine2026
Effectiveness of tiger milk mushroom (Lignosus rhinocerus) on asthma: a systematic review.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory airway disease with a rising global prevalence and impact on quality of life. Conventional therapeutics such as corticosteroids and β2-agonists are associated with various long-term adverse effects and are costly. This has prompted the exploration of natural therapies such as the tiger milk mushroom (TMM), also known as Lignosus rhinocerus. Native to Southeast Asia, this medicinal mushroom has been traditionally used for respiratory health. TMM is known to be rich in bioactive compounds including polysaccharides and polyphenols, and has shown anti-inflammatory and immunomodulatory properties. This systematic review aimed to investigate its effects in asthma. Animal studies demonstrated significant suppression of eosinophil infiltration, Th2 cytokines (IL-4, 5, and 13), IgE levels, and attenuated airway remodeling. In vitro studies confirmed bronchorelaxation effects mediated through calcium channel modulation. A single human study reported a decrease in inflammatory and antioxidant markers (IL-1β, IL-8, and MDA), improved lung function and quality of life. Overall, TMM has shown promising potential as an anti-asthmatic agent. However, current evidence is largely preclinical and has a limited scope. Further high-quality larger scale trials are needed to validate its efficacy and safety in humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.